Methotrexate toxicity

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:565782Y14
Who is this for?
Show terms as
3FDA treatments11Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Methotrexate toxicity refers to the harmful side effects that can happen when the drug methotrexate causes damage to the body. Methotrexate is a medicine used to treat many conditions, including certain cancers (like leukemia and lymphoma), rheumatoid arthritis, psoriasis, and other autoimmune diseases. It works by blocking a key process that cells need to grow and divide. While this makes it useful for fighting cancer and calming overactive immune systems, it can also harm healthy cells — especially in the bone marrow, digestive tract, liver, kidneys, and lungs. Toxicity can happen at high doses (like those used in cancer treatment) or even at lower doses used for arthritis or skin conditions, especially if the drug builds up in the body over time. Risk is higher in people with kidney problems, low folate levels, or certain genetic variations that affect how their body processes the drug. Symptoms can range from mild nausea and mouth sores to serious problems like bone marrow failure, liver scarring, lung inflammation, and kidney damage. Treatment for methotrexate toxicity depends on how severe it is. Mild cases may just need the drug to be stopped or the dose reduced. Serious cases may require a rescue medicine called leucovorin (folinic acid), which helps protect healthy cells. Supportive care — such as fluids, blood transfusions, or treatment for infections — may also be needed. With prompt recognition and treatment, many people recover fully, but severe toxicity can be life-threatening.

Key symptoms:

Mouth sores or ulcersNausea, vomiting, or stomach painUnusual tiredness or weaknessLow white blood cell count, making infections more likelyLow platelet count, causing easy bruising or bleedingLow red blood cell count (anemia), causing pale skin and shortness of breathLiver damage, which may cause yellowing of the skin or eyes (jaundice)Kidney problems, including reduced urine outputDry cough or shortness of breath (lung inflammation)Skin rash or increased sensitivity to sunlightHair thinning or hair lossHeadache, confusion, or seizures (especially with high-dose treatment)Diarrhea

Clinical phenotype terms (22)— hover any for plain English
Megaloblastic anemiaHP:0001889Interstitial pneumonitisHP:0006515
Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Jan 2012

Voraxaze: FDA approved

Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

3 available

Fusilev

levoleucovorin· Acrotech Biopharma LLC

diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients

Leucovorin calcium

Leucovorin· Immunex Corporation

Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent over dosages of folic acid antagonists

Voraxaze

glucarpidase· BTG International Inc.Orphan Drug

Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.

No actively recruiting trials found for Methotrexate toxicity at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Methotrexate toxicity community →

Specialists

11 foundView all specialists →
KM
Kjeld Schmiegelow, M.D.
Specialist
PI on 1 active trial
AM
Antonio Omuro, MD
STANFORD, CA
Specialist
PI on 3 active trials1 Methotrexate toxicity publication
MP
Mikael Eriksson, MD PhD
Specialist
PI on 2 active trials
RM
Roderick Johnson, MD
Specialist
PI on 2 active trials
RB
Richard E. Champlin, BS,MD
Specialist
PI on 1 active trial
JM
Jennifer H Foster, MD
Specialist
PI on 1 active trial
SC
Suzanne Kincaid, CCRA
Specialist
PI on 1 active trial
PM
Pinki Prasad, MD
NEW ORLEANS, LA
Specialist
PI on 1 active trial
JT
John A Thompson
Specialist
2 Methotrexate toxicity publications
CF
Christopher P Fox
Specialist
2 Methotrexate toxicity publications
MH
Maha A Helal
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Fusilev(levoleucovorin)Acrotech Biopharma LLC

Travel Grants

No travel grants are currently matched to Methotrexate toxicity.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Methotrexate toxicityForum →

No community posts yet. Be the first to share your experience with Methotrexate toxicity.

Start the conversation →

Latest news about Methotrexate toxicity

No recent news articles for Methotrexate toxicity.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What signs of toxicity should I watch for at home, and when should I go to the emergency room?,How often do I need blood tests to monitor for side effects, and what are you checking for?,Should I take folic acid supplements, and if so, how much and when?,Are there any medications, supplements, or foods I should avoid while taking methotrexate?,Could my genetics affect how my body handles methotrexate, and should I be tested?,What happens to my underlying condition if methotrexate has to be stopped due to toxicity?,Is leucovorin or glucarpidase available at this hospital if I develop serious toxicity?

Common questions about Methotrexate toxicity

What is Methotrexate toxicity?

Methotrexate toxicity refers to the harmful side effects that can happen when the drug methotrexate causes damage to the body. Methotrexate is a medicine used to treat many conditions, including certain cancers (like leukemia and lymphoma), rheumatoid arthritis, psoriasis, and other autoimmune diseases. It works by blocking a key process that cells need to grow and divide. While this makes it useful for fighting cancer and calming overactive immune systems, it can also harm healthy cells — especially in the bone marrow, digestive tract, liver, kidneys, and lungs. Toxicity can happen at high d

Which specialists treat Methotrexate toxicity?

11 specialists and care centers treating Methotrexate toxicity are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.